What Asimov does: It provides an integrated synthetic biology platform for biopharma, combining cloud-based software for designing, simulating, and optimizing genetic systems with engineered GMP host cells used for therapeutic production. How its products work: The software lets users design and run simulations of genetic circuits and optimize production processes, while engineered cell lines are used to express proteins or produce viral vectors; services include process development and stability studies. How it differs from competitors: It bundles an end-to-end suite—genetic design software, in-house cell-line development, and process development—along with a performance guarantee, such as a 4 g/L monoclonal antibody titer promise, reducing client risk. What its goal is: To help biopharma customers achieve high yields and scalable production of biologics, gene therapies, and programmable medicines through a tightly integrated platform.
Company Size
51-200
Company Stage
Series B
Total Funding
$204.7M
Headquarters
Boston, Massachusetts
Founded
2017
See people who can refer or advise you
Help us improve and share your feedback! Did you find this helpful?